We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Portable Immunoassay System Advances Toward Point-of-Care Biomarker Testing

By HospiMedica International staff writers
Posted on 11 Jun 2026

Proxim Diagnostics Corp. More...

(Santa Clara, CA, USA) has announced that its Profile System, a handheld point-of-care immunoassay platform, has completed development. The milestone includes completion of the reader, single-use cartridge, and initial manufacturing capability. The fully automated, portable system is designed to deliver high-sensitivity biomarker testing at the point of care and is now positioned for production readiness and potential partnerships in acute care and research applications.

The technology integrates a disposable cartridge with a compact reader to execute immunoassays intended to deliver centralized laboratory performance closer to the bedside. The Profile System is designed as a flexible architecture capable of supporting multiple assay types on the same handheld reader. The company indicates this may enable a broad test menu over time, including research‑use‑only (RUO) assays for biopharma customers and future clinical assays that would be subject to applicable regulatory requirements.

Proxim is advancing applications in acute care biomarkers, including cardiac and inflammatory markers where rapid point‑of‑care results can support time‑critical decisions. The platform has demonstrated key analytical traits associated with high‑sensitivity troponin testing. In testing of its high‑sensitivity troponin I assay, the system achieved an 81% detectable rate in the normal population.

The company also highlights RUO assays for cytokines such as interleukin‑6, interferon‑gamma, and CXCL9 for inpatient and outpatient use by biopharma clients developing T‑cell engager therapies, where rapid cytokine measurements may support prediction, monitoring, and management of cytokine release syndrome (CRS), immune effector cell‑associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis (HLH), and other immuno‑oncology therapy‑related adverse effects.

“Completing development of our handheld reader, cartridge, and initial manufacturing capacity is a major milestone for Proxim. We now have a fully developed product platform that is ready to support high-value clinical and RUO opportunities,” said Mikhail Briman, Ph.D., CEO and co-founder of Proxim Diagnostics.

“Our goal has always been to bring the sensitivity and precision of centralized laboratory testing into a portable point-of-care format, and this achievement puts us in a strong position to engage strategic partners and customers across biopharma, acute care, women’s health, and other important clinical and research areas,” added Briman.

Related Links
Proxim Diagnostics


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Desk Aneroid Sphyg
Diagnostix 750D+
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: The tool analyzes 3D time-of-flight MR angiography to measure brain vessel length, radius, volume, branching, tortuosity, and other structural features. (Photo courtesy of University of Rochester Medical Center)

MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.